Corbus appoints Leonardo Viana Nicacio as CMO; base salary $545K, equity $2.1M

Corbus Pharmaceuticals Holdings, Inc.

Dr. Nicacio appointed CMO effective Aug 3, 2026; base salary $545K, target bonus up to 40%, equity inducement awards of $2.1M.
He brings ADC and HPV-driven oncology experience, previously CMO at Protara, VP at Seagen (TIVDAK), and roles at AstraZeneca, Flatiron Health.
Corbus expects to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC summer 2026; topline CANYON-1 obesity study data late summer 2026.
Employment agreement for 2 years, includes non-compete (6 months post) and non-solicitation (12 months post), severance provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.